Treating Migraine with Contraceptives

Overview

Journal Neurol Sci

Specialty Neurology

Date 2017 May 21

PMID 28527064

Citations 15

Authors

Gianni Allais

Giulia Chiarle

Silvia Sinigaglia

Gisella Airola

Paola Schiapparelli

Fabiola Bergandi

Chiara Benedetto

Affiliations

Soon will be listed here.

Abstract

At least 18% of women suffers from migraine. Clinically, there are two main forms of migraine: migraine with aura (MA) and migraine without aura (MO) and more than 50% of MO is strongly correlated to the menstrual cycle. The high prevalence of migraine in females, its correlation with the menstrual cycle and with the use of combined hormonal contraceptives (CHCs) suggest that the estrogen drop is implicated in the pathogenesis of the attacks. Although CHCs may trigger or worsen migraine, their correct use may even prevent or reduce some forms of migraine, like estrogen withdrawal headache. Evidence suggested that stable estrogen levels have a positive effect, minimising or eliminating the estrogenic drop. Several contraceptive strategies may act in this way: extended-cycle CHCs, CHCs with shortened hormone-free interval (HFI), progestogen-only contraceptives, CHCs containing new generation estrogens and estrogen supplementation during the HFI.

Citing Articles

The influence of sex on neuroimmune communication, pain, and physiology.

Alexander S, Green A, Debner E, Ramos Freitas L, Abdelhadi H, Szabo-Pardi T Biol Sex Differ. 2024; 15(1):82.

PMID: 39439003 PMC: 11494817. DOI: 10.1186/s13293-024-00660-w.

Hormonal Contraceptive Influence on Baseline Vestibular/Ocular Symptomatology and Provocation for Concussion.

Moran R, Guin J, Roehmer C, Murray N Orthop J Sports Med. 2024; 12(8):23259671241259735.

PMID: 39157027 PMC: 11329980. DOI: 10.1177/23259671241259735.

The influence of factors associated with past reproductive histories on migraines in middle-aged premenopausal women: a nationwide population-based study in Republic of Korea.

Kim S, Na S, Kim Y, Bae D, An J, Park J Front Neurol. 2024; 15:1406443.

PMID: 38915802 PMC: 11194392. DOI: 10.3389/fneur.2024.1406443.

Considerations for hormonal therapy in migraine patients: a critical review of current practice.

van Lohuizen R, Paungarttner J, Lampl C, MaassenVanDenBrink A, Al-Hassany L Expert Rev Neurother. 2023; :1-21.

PMID: 38112066 PMC: 10791067. DOI: 10.1080/14737175.2023.2296610.

The physical impact of migraines on female chiropractic patients: A qualitative study.

Pirthiraj A, Bhagwan R Health SA. 2023; 28:2283.

PMID: 37927942 PMC: 10623481. DOI: 10.4102/hsag.v28i0.2283.

References

Aegidius K, Zwart J, Hagen K, Schei B, Stovner L . Oral contraceptives and increased headache prevalence: the Head-HUNT Study. Neurology. 2006; 66(3):349-53. DOI: 10.1212/01.wnl.0000196481.57994.09. View

Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni G . Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993; 33(7):385-9. DOI: 10.1111/j.1526-4610.1993.hed3307385.x. View

Nappi R, Terreno E, Sances G, Martini E, Tonani S, Santamaria V . Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception. 2013; 88(3):369-75. DOI: 10.1016/j.contraception.2013.02.001. View

Magos A, ZILKHA K, Studd J . Treatment of menstrual migraine by oestradiol implants. J Neurol Neurosurg Psychiatry. 1983; 46(11):1044-6. PMC: 491742. DOI: 10.1136/jnnp.46.11.1044. View

Buse D, Loder E, Gorman J, Stewart W, Reed M, Fanning K . Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013; 53(8):1278-99. DOI: 10.1111/head.12150. View

Alkema L, Kantorova V, Menozzi C, Biddlecom A . National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis. Lancet. 2013; 381(9878):1642-52. DOI: 10.1016/S0140-6736(12)62204-1. View

Calhoun A . Combined hormonal contraceptives: is it time to reassess their role in migraine?. Headache. 2012; 52(4):648-60. DOI: 10.1111/j.1526-4610.2011.02051.x. View

Morotti M, Remorgida V, Venturini P, Ferrero S . Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. Eur J Obstet Gynecol Reprod Biol. 2014; 183:178-82. DOI: 10.1016/j.ejogrb.2014.10.029. View

Calhoun A, Ford S, Pruitt A . The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series. Headache. 2012; 52(8):1246-53. DOI: 10.1111/j.1526-4610.2012.02211.x. View

10.

MacGregor A . Migraine associated with menstruation. Funct Neurol. 2001; 15 Suppl 3:143-53. View

11.

MacGregor E . Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004; 3(6):354-61. DOI: 10.1016/S1474-4422(04)00768-9. View

12.

Nappi R, Sances G, Allais G, Terreno E, Benedetto C, Vaccaro V . Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception. 2011; 83(3):223-8. DOI: 10.1016/j.contraception.2010.07.024. View

13.

Bonassi Machado R, Pereira A, Coelho G, Neri L, Martins L, Luminoso D . Epidemiological and clinical aspects of migraine in users of combined oral contraceptives. Contraception. 2010; 81(3):202-8. DOI: 10.1016/j.contraception.2009.09.006. View

14.

Somerville B, CAREY H . The use of continuous progestogen contraception in the treatment of migraine. Med J Aust. 1970; 1(21):1043-5. DOI: 10.5694/j.1326-5377.1970.tb84395.x. View

15.

Coffee A, Sulak P, Kuehl T . Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception. 2007; 75(6):444-9. DOI: 10.1016/j.contraception.2007.01.014. View

16.

Sulak P, Willis S, Kuehl T, Coffee A, Clark J . Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007; 47(1):27-37. DOI: 10.1111/j.1526-4610.2007.00650.x. View

17.

Jayaraman A, Pike C . Progesterone attenuates oestrogen neuroprotection via downregulation of oestrogen receptor expression in cultured neurones. J Neuroendocrinol. 2008; 21(1):77-81. PMC: 2692678. DOI: 10.1111/j.1365-2826.2008.01801.x. View

18.

Couturier E, Bomhof M, Neven A, van Duijn N . Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003; 23(4):302-8. DOI: 10.1046/j.1468-2982.2003.00516.x. View

19.

Merki-Feld G, Imthurn B, Seifert B, Merki L, Agosti R, Gantenbein A . Desogestrel-only contraception may reduce headache frequency and improve quality of life in women suffering from migraine. Eur J Contracept Reprod Health Care. 2013; 18(5):394-400. DOI: 10.3109/13625187.2013.814769. View

20.

Nappi R, Sances G, Brundu B, De Taddei S, Sommacal A, Ghiotto N . Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Hum Reprod. 2005; 20(12):3423-8. DOI: 10.1093/humrep/dei260. View